PRTA Prothena Corporation plc - marketcomposite.com

PRTA - Prothena Corporation plc8:00:00 PM 4/25/2024

Price

$20.56

+ 0.00 (0.00%)

Prothena Corporation plc, a clinical-stage neuroscience company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, an antibody that is in Phase I clinical trial for the treatment of ATTR amyloidosis. Its discovery-stage programs include Tau for treating Alzheimer's disease, progressive supranuclear palsy, frontotemporal dementia, chronic traumatic encephalopathy, and other tauopathies; AÃ, or Amyloid Beta, a protein for the treatment of Alzheimer's disease; TDP-43 for amyotrophic lateral sclerosis and frontotemporal dementia; and other products for neurodegeneration. The company has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. Prothena Corporation plc was founded in 2012 and is based in Dublin, Ireland.

Stock Chart

Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from

Finra

Moving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.

Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.

Topics

30d

Biotechnology-1.70%

Peers

30d

ALKS-0.90%

ALNY-0.10%

AMRN-2.30%

leak data

Stock news

PRTA

Earnings Preview: Prothena (PRTA) Q1 Earnings Expected to Decline04-25-2024 14:01:46 PM

Prothena (PRTA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRTA

Prothena Announces Review on Birtamimab Mechanism of Action and Pharmacological Characteristics Published in Leukemia & Lymphoma04-15-2024 20:05:00 PM

DUBLIN, April 15, 2024--Prothena today announced a publication related to the mechanism of action, pharmacological characteristics, and clinical utility of birtamimab.

PRTA

Race To Treat Alzheimer's Disease Is Heating Up Despite Eli Lilly's Setback03-28-2024 12:00:21 PM

The Alzheimer's treatment space is heating up — and could soon leave Eli Lilly's embattled drug, donanemab, in the dust, experts say.

PRTA

CHMP to Delay Nod on Biogen (BIIB), Eisai's Alzheimer's Drug03-26-2024 15:21:00 PM

Per Biogen (BIIB)/Eisai, the delay in CHMP recommendation for lecanemab is entirely related to procedural reasons at the EMA and is not related to the companies' regulatory filing.

PRTA

Prothena to Participate in Upcoming Healthcare Conferences03-05-2024 21:05:00 PM

DUBLIN, March 05, 2024--Prothena today announced that members of its senior management team will participate in two upcoming investor conferences in March.

PRTA

Prothena Appoints David Ford to Newly Created Chief People Officer Position03-04-2024 21:05:00 PM

DUBLIN, March 04, 2024--Prothena today announced that it has named David Ford to a newly created position of Chief People Officer.

PRTA

Prothena Announces Appointment of Daniel G. Welch as Director and Chair Designate02-21-2024 21:05:00 PM

DUBLIN, February 21, 2024--Prothena announced today the appointment of Daniel G. Welch to its Board of Directors as an independent director and Chair Designate.

PRTA

Prothena Full Year 2023 Earnings: Beats Expectations02-17-2024 12:45:51 PM

Prothena ( NASDAQ:PRTA ) Full Year 2023 Results Key Financial Results Revenue: US$91.4m (up 70% from FY 2022). Net...

PRTA

Prothena (PRTA) Q4 Earnings Miss Estimates on Higher R&D Expense02-16-2024 18:33:00 PM

Prothena (PRTA) posts a wider-than-expected loss in the fourth quarter on lower revenues and higher costs.

PRTA

Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript02-16-2024 15:33:51 PM

Prothena Corporation plc (NASDAQ:PRTA) Q4 2023 Earnings Call Transcript February 15, 2024 Prothena Corporation plc misses on earnings expectations. Reported EPS is $-1.26 EPS, expectations were $-1.23. PRTA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day ladies and […]